Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
Christer Ahlberg discusses HEEALING1 ahead of topline results
At Swiss Nordic Bio 2026, Cinclus Pharma CEO Christer Ahlberg joined BiotechTV to discuss the company’s ongoing Phase III HEEALING1 trial.
Christer Ahlberg presents at Biostock Investing in Life Science in Stockholm
Watch the presentation by Cinclus Pharma's CEO Christer Ahlberg at Biostock Investing in Life Science 2026 in Stockholm from September 22.
Christer Ahlberg interviewed by Redeye about the Q2 report and HEEALING1
Cinclus Pharma CEO Christer Ahlberg discusses the Q2 2026 Interim Report and provides an update on the Phase III HEEALING1 trial in an interview with Redeye.
Watch the full presentation from Jefferies Global Healthcare Conference
CEO Christer Ahlberg presents the company and the drug candidate, linaprazan glurate.
Cinclus Pharma in media
Interview with Christer Ahlberg in BioStock
2026-06-09Read article about Cinclus Pharma with interview with CEO Christer Ahlberg from BioStock (in Swedish).
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
